Novotech Health Holdings gets $505 million of debt facilities

By Rebecca Melvin

Concord, N.H., Jan. 19 – Novotech Health Holdings Pte. Ltd. has completed a $505 million debt refinancing transaction including a revolver and growth facility, according to a company release Wednesday.

The financing replaces the company’s existing debt facilities which were due to expire in 2023. It further optimizes Novotech’s balance sheet, establishes a fit-for-purpose capital structure and provides additional support for the execution of the company’s growth initiatives. Both existing and new lenders participated in this refinancing transaction.

Novotech chief executive officer John Moller said, “We are grateful for the support and recognition we received from multiple global investors that participated in the private placement transaction. In addition, we are very pleased to receive continued endorsement from our existing investors. We look forward to accelerating our growth by pursuing various strategic M&A and tech enablement initiatives and seek to better serve our biotech and pharmaceutical clients and support the clinical research industry in the development of a wide spectrum of therapeutic areas.”

The Asia Pacific biotech contact research organization is based in Australia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.